Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL

Peter Martin, Nancy L. Bartlett, Julio C. Chavez, John L. Reagan, Sonali M. Smith, Ann S. LaCasce, Jeffrey Jones, James Drew, Chengqing Wu, Erin Mulvey, Maria V. Revuelta, Leandro Cerchietti, John P. Leonard

Blood (2022) 139 (8): 1147–1159.

https://doi.org/10.1182/blood.2021011679

Published: 2022

Includes: Supplemental data

Journal Articles

Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy

Blood (2021) 137 (2): 216–231.

https://doi.org/10.1182/blood.2020006073

Published: 2021

Includes: Supplemental data

Journal Articles

Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience

Susan O’Brien, Richard R. Furman, Steven Coutre, Ian W. Flinn, Jan A. Burger, Kristie Blum, Jeff Sharman, William Wierda, Jeffrey Jones, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Ying Luan, Danelle F. James, Alvina D. Chu, John C. Byrd

Blood (2018) 131 (17): 1910–1919.

https://doi.org/10.1182/blood-2017-10-810044

Published: 2018

Includes: Supplemental data

Journal Articles

Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies

Ian W. Flinn, Susan O’Brien, Brad Kahl, Manish Patel, Yasuhiro Oki, Francine F. Foss, Pierluigi Porcu, Jeffrey Jones, Jan A. Burger, Nitin Jain, Virginia M. Kelly, Kerstin Allen, Mark Douglas, Jennifer Sweeney, Patrick Kelly, Steven Horwitz

Blood (2018) 131 (8): 877–887.

https://doi.org/10.1182/blood-2017-05-786566

Published: 2018

Includes: Supplemental data

Journal Articles

Acalabrutinib with Obinutuzumab in Relapsed/Refractory and Treatment-Naive Patients with Chronic Lymphocytic Leukemia: The Phase 1b/2 ACE-CL-003 Study

Jennifer A. Woyach, MD, Farrukh T. Awan, MD MS, Mojgan Jianfar, MD, Kerry A. Rogers, MD, Jeffrey Jones, MD MPH, Todd Covey, PhD, Ahmed Hamdy, MD, Raquel Izumi, PhD, Priti Patel, MD, Min Hui Wang, PhD, John C. Byrd, MD

Blood (2017) 130 (Supplement 1): 432.

https://doi.org/10.1182/blood.V130.Suppl_1.432.432

Published: 2017

Journal Articles

Safety, Efficacy and MRD Negativity of a Combination of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331)

Ian W. Flinn, MD PhD, John G. Gribben, MDDSc FMedSci, Martin J.S. Dyer, William G Wierda, MD PhD, Michael B. Maris, Richard R. Furman, MD, Peter Hillmen, MBChB, PhD, Jeffrey Jones, MD, Swami P. Iyer, MD, Surai Jones, Yanwen Jiang, Daniela Soriano Pignataro, Kathryn Humphrey, Mehrdad Mobasher, Thomas J. Kipps, MD

Blood (2017) 130 (Supplement 1): 430.

https://doi.org/10.1182/blood.V130.Suppl_1.430.430

Published: 2017

Journal Articles

A Validated Risk Model for Overall Survival in Relapsed/Refractory Chronic Lymphocytic Leukemia Applicable to Patients Treated with Novel Therapies and Standard of Care

Blood (2017) 130 (Supplement 1): 4303.

https://doi.org/10.1182/blood.V130.Suppl_1.4303.4303

Published: 2017

Journal Articles

Analysis of PET-CT to Identify Richter's Transformation in 167 Patients with Disease Progression Following Kinase Inhibitor Therapy

Anthony R. Mato, MD, William G Wierda, MD PhD, Matthew S. Davids, MD, Bruce D. Cheson, MD, Steven Coutre, MD, Michael Choi, MD, Richard R. Furman, Leonard Heffner, MD, Paul M. Barr, MD, Herbert Eradat, Lang Zhou, Maria Verdugo, MD, Jalaja Potluri, Jeffrey Jones, MD

Blood (2017) 130 (Supplement 1): 834.

https://doi.org/10.1182/blood.V130.Suppl_1.834.834

Published: 2017

Journal Articles

A Phase 2 Trial of Early Intervention with Ibrutinib in Patients with Asymptomatic, High-Risk CLL

Farrukh T. Awan, MD MS, Shanmugapriya Thangavadivel, PhD, David Weiss, Lai Wei, PhD, Jennifer A. Woyach, MD, Kerry A. Rogers, MD, Jeffrey Jones, MD, Leslie Andritsos, MD, Natarajan Muthusamy, DVM,PhD, Barbara Andersen, PhD, John C. Byrd, MD

Blood (2017) 130 (Supplement 1): 1748.

https://doi.org/10.1182/blood.V130.Suppl_1.1748.1748

Published: 2017

Journal Articles

Venetoclax (VEN) Is Active in Chronic Lymphocytic Leukemia (CLL) Relapsed or Refractory to More Than One B-Cell Receptor Pathway Inhibitor (BCRi)

William G Wierda, MD PhD, Matthew S. Davids, MD, Richard R. Furman, Bruce D. Cheson, MD, Paul M. Barr, MD, Herbert Eradat, Leonard Heffner, MD, Jeffrey Jones, MD, Lang Zhou, Maria Verdugo, MD, Rod A. Humerickhouse, Jalaja Potluri, Michael Choi, MD

Blood (2017) 130 (Supplement 1): 3025.

https://doi.org/10.1182/blood.V130.Suppl_1.3025.3025

Published: 2017

Journal Articles

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

Blood (2017) 129 (5): 553–560.

https://doi.org/10.1182/blood-2016-01-689422

Published: 2017

Journal Articles

Natural History of Non-Infectious, Ibrutinib-Attributable Adverse Events Leading to Alternative BTK Inhibitor Use in CLL

Polina Shindiapina, MD PhD, Soun Khountham, Kerry A. Rogers, MD, Jeffrey Jones, MD MPH, Leslie Andritsos, MD, Kami J. Maddocks, MD, Joseph M. Flynn, DO, MPH, Jennifer A. Woyach, MD, John C. Byrd, MD, Farrukh T. Awan

Blood (2016) 128 (22): 4385.

https://doi.org/10.1182/blood.V128.22.4385.4385

Published: 2016

Journal Articles

Updated Results from a Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL) and Richter's Transformation or Ibrutinib for Patients with Ibrutinib-Resistant Clones

Jennifer A. Woyach, MD, Amy S. Ruppert, MAS, Farrukh T. Awan, Jeffrey Jones, MD MPH, Leslie A. Andritsos, MD, Sharon Waymer, Gerard Lozanski, MD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD

Blood (2016) 128 (22): 4386.

https://doi.org/10.1182/blood.V128.22.4386.4386

Published: 2016

Journal Articles

Major Bleeding Complications Among Patients Treated with Ibrutinib and Concomitant Antiplatelet, Anticoagulant, or Supplemental Therapy

Aaron Pavlik, PharmD, Hallie Barr, PharmD, BCOP, Emily Dotson, PharmD, BCOP, John C. Byrd, MD, Kristie A. Blum, MD, Farrukh T. Awan, Jennifer A. Woyach, MD, Kami J. Maddocks, MD, Beth A Christian, MD, Jeffrey Jones, MD MPH

Blood (2016) 128 (22): 4387.

https://doi.org/10.1182/blood.V128.22.4387.4387

Published: 2016

Journal Articles

Near-Tetraploidy Is Strongly Associated with Development of Richter's Transformation in Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib

Blood (2016) 128 (22): 3198.

https://doi.org/10.1182/blood.V128.22.3198.3198

Published: 2016

Journal Articles

Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia

Susan M. O'Brien, MD, Richard R. Furman, MD, Steven E. Coutre, MD, Ian W. Flinn, MD PhD, Jan Burger, MD PhD, Kristie Blum, MD, Jeff Sharman, MD, William G. Wierda, MD PhD, Jeffrey Jones, MD MPH, Weiqiang Zhao, MD PhD, Nyla A. Heerema, PhD, Amy J. Johnson, PhD, Ying Luan, PhD, Danelle F. James, MD MAS, Alvina D. Chu, MD, John C. Byrd, MD

Blood (2016) 128 (22): 233.

https://doi.org/10.1182/blood.V128.22.233.233

Published: 2016

Journal Articles

Trametinib for the Treatment of IGHV4-34, MAP2K1 Mutant Variant Hairy Cell Leukemia

Leslie A. Andritsos, MD, Mirela Anghelina, MD, Nicole R. Grieselhuber, MD PhD, Sameek Roychowdhury, MD PhD, Julie Reeser, PhD, Cynthia Timmers, PhD, Aharon G. Freud, MD PhD, James S. Blachly, MD, David M. Lucas, PhD, Gerard Lozanski, MD, Jeffrey Jones, MD MPH, Kerry A. Rogers, MD, Weiqiang Zhao, MD PhD, Michael R. Grever, MD

Blood (2016) 128 (22): 5598.

https://doi.org/10.1182/blood.V128.22.5598.5598

Published: 2016

Journal Articles

Management and Outcomes of Atrial Fibrillation in Patients Receiving Ibrutinib for Hematologic Malignancies at a Single Center

Tracy E Wiczer, PharmD, BCOP, Lauren B Levine, PharmD, BCOP, Jessica Brumbaugh, Jessica Coggins, Qiuhong Zhao, MS, Amy S. Ruppert, MAS, Anli McCoy, PharmD, Kami J. Maddocks, MD, Beth A Christian, MD, Kerry A. Rogers, MD, Leslie Andritsos, MD, Samantha Jaglowski, MD MPH, Steven M Devine, MD, Pierluigi Porcu, MD, Jennifer A. Woyach, MD, Jeffrey Jones, MD MPH, Michael R. Grever, MD, John C. Byrd, MD, Farrukh T. Awan

Blood (2016) 128 (22): 2040.

https://doi.org/10.1182/blood.V128.22.2040.2040

Published: 2016

Journal Articles

Presence of a Translocation Is Associated with Short Time to Treatment from Diagnosis in IGHV Mutated Chronic Lymphocytic Leukemia (CLL) Patients

Nyla A. Heerema, PhD, Qiuhong Zhao, MS, Amy S. Ruppert, MAS, Heather Breidenbach, Jeffrey Jones, MD MPH, Leslie A. Andritsos, MD, Jennifer A. Woyach, MD, Farrukh T. Awan, Meixiao Long, MD PhD, Amber Gordon, MLS, Caitlin Coombes, BA, John C. Byrd, MD, Natarajan Muthusamy, DVM, PhD

Blood (2016) 128 (22): 4372.

https://doi.org/10.1182/blood.V128.22.4372.4372

Published: 2016

Journal Articles

the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL

Blood (2016) 128 (22): 55.

https://doi.org/10.1182/blood.V128.22.55.55

Published: 2016

NARROW

Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL

Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy

Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience

Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies

Acalabrutinib with Obinutuzumab in Relapsed/Refractory and Treatment-Naive Patients with Chronic Lymphocytic Leukemia: The Phase 1b/2 ACE-CL-003 Study

Safety, Efficacy and MRD Negativity of a Combination of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331)

A Validated Risk Model for Overall Survival in Relapsed/Refractory Chronic Lymphocytic Leukemia Applicable to Patients Treated with Novel Therapies and Standard of Care

Analysis of PET-CT to Identify Richter's Transformation in 167 Patients with Disease Progression Following Kinase Inhibitor Therapy

A Phase 2 Trial of Early Intervention with Ibrutinib in Patients with Asymptomatic, High-Risk CLL

Venetoclax (VEN) Is Active in Chronic Lymphocytic Leukemia (CLL) Relapsed or Refractory to More Than One B-Cell Receptor Pathway Inhibitor (BCRi)

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

Natural History of Non-Infectious, Ibrutinib-Attributable Adverse Events Leading to Alternative BTK Inhibitor Use in CLL

Updated Results from a Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL) and Richter's Transformation or Ibrutinib for Patients with Ibrutinib-Resistant Clones

Major Bleeding Complications Among Patients Treated with Ibrutinib and Concomitant Antiplatelet, Anticoagulant, or Supplemental Therapy

Near-Tetraploidy Is Strongly Associated with Development of Richter's Transformation in Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib

Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia

Trametinib for the Treatment of IGHV4-34, MAP2K1 Mutant Variant Hairy Cell Leukemia

Management and Outcomes of Atrial Fibrillation in Patients Receiving Ibrutinib for Hematologic Malignancies at a Single Center

Presence of a Translocation Is Associated with Short Time to Treatment from Diagnosis in IGHV Mutated Chronic Lymphocytic Leukemia (CLL) Patients

the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only